KANSAS CITY, MO -- (MARKET WIRE) -- 06/30/05 -- New data presented at the European Neurological Society Meeting (ENS) demonstrated key clinical and magnetic resonance imaging (MRI) effects of COPAXONE® (glatiramer acetate injection) in the treatment of relapsing-remitting multiple sclerosis (RRMS). Results highlighted sustained beneficial effects on cerebral axonal injury and the value of starting COPAXONE® treatment early to slow the accumulation of long-term disability as measured by the Expanded Disability Status Scale (EDSS).
MRS results suggest beneficial effect of COPAXONE® on cerebral axonal injury
Brain n-acetylaspartate (NAA) levels, a marker of neuronal integrity and function, are measured by magnetic resonance spectroscopy (MRS). An increase in brain NAA levels relative to creatinine (NAA/Cr ratios) indicates a recovery of injured nerve cells or neurons in the brain. Preventing or minimizing damage to nerve cells is critical in reducing long-term disability in multiple sclerosis.
Click here to continue
Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You